Publication:
XELIRI plus bevacizumab compared with FOLFIRI plus bevacizumab as first-line setting in patients with metastatic colorectal cancer: experiences at two-institutions.

Loading...
Thumbnail Image

relationships.isOrgUnitOf

Program

relationships.isAuthorOf

Author

BILICI, A

KAYA, S

Oven, Ustaalioglu

YILDIZ, R

TEMIZ, S

Seker, MESUT

AKSU, G

CABUK, D

GUMUS, M

Advisor

Language

Publisher

Journal Title

Journal ISSN

Volume Title

Abstract

Description

Source

Keywords

Keywords

Citation

UYGUN K., BILICI A., KAYA S., Oven U., YILDIZ R., TEMIZ S., Seker M., AKSU G., CABUK D., GUMUS M., -XELIRI plus bevacizumab compared with FOLFIRI plus bevacizumab as first-line setting in patients with metastatic colorectal cancer: experiences at two-institutions.-, Asian Pacific journal of cancer prevention : APJCP, cilt.14, ss.2283-8, 2013

Collections

Endorsement

Review

Supplemented By

Referenced By

1

Views

27

Downloads

View PlumX Details


Sustainable Development Goals

Item type:Goal,